Open AccessTargeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity
Author(s) -
Gloria Ciniero,
Francesco Gentile,
Ahmed H. Elmenoufy,
Emeline CrosPerrial,
F. G. West,
Michael Weinfeld,
Marco A. Deriu,
Lars Petter Jordheim,
Jack A. Tuszyński
Publication year - 2021
Publication title -
biomedical science and engineering
Language(s) - English
Resource type - Journals
ISSN - 2531-9892
DOI - 10.4081/bse.2021.164
Subject(s) - ercc1 , drug resistance , cancer , cancer research , cancer cell , biology , drug , pharmacology , gene , chemistry , nucleotide excision repair , dna repair , genetics
New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom